Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma
Authors:
Open Access
- 21 May 2014
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 136 (2) , 289-298
Abstract
Histone H3 lysine 9 trimethylation (H3K9me3) is associated with transcriptional repression and regulated by histone lysine methyltransferases such as SUV39H1 and ESET. However, the functional roles of these enzymes in hepatocellular carcinoma (HCC) remain uncertain. In this study, we conducted loss‐of‐function assays for HCC cells. SUV39H1 knockdown but not ESET knockdown reduced H3K9me3 levels and impaired HCC cell growth and sphere formation. The pharmacological inhibition of SUV39H1 by chaetocin resulted in cell growth inhibition and inducing cellular apoptosis in culture and xenograft subcutaneous tumors. Real‐time polymerase chain reaction analysis indicated high levels of SUV39H1 expression in 24 of 42 (57.1%) HCC surgical samples compared with corresponding nontumor tissues. Immunohistochemistry identified high levels of H3K9me3 and ESET proteins in 23 (54.8%) and 29 (69.0%) tumor tissues, respectively. However, these proteins' expressions were only observed in biliary epithelial cells and periportal hepatocytes of nontumor tissues. Expression levels of SUV39H1 but not those of ESET were significantly correlated with H3K9me3 levels. The cumulative HCC recurrence rate was significantly higher for patients with elevated SUV39H1 expression and H3K9me3 levels. In conclusion, our data indicate that elevated SUV39H1 expression and high levels of H3K9me3 have important roles in HCC development and progression. Therefore, the pharmacological inhibition of SUV39H1 may be a promising therapeutic approach for HCC treatment.Keywords
Funding Information
- Global COE Program (Global Center for Education and Research in Immune System Regulation and Treatment)
- Ministry of Education, Culture, Sports, Science and Technology, Japan
- Core Research for Evolutional Science and Technology (CREST)
- Japan Science and Technology Corporation (JST)
- Foundation for the Promotion of Cancer Research
This publication has 34 references indexed in Scilit:
- Cancer Epigenetics: From Mechanism to TherapyCell, 2012
- 3‐Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor‐initiating hepatocellular carcinoma cellsInternational Journal of Cancer, 2011
- Regulation of chromatin by histone modificationsCell Research, 2011
- Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancersNature Reviews Cancer, 2010
- Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinomaHuman Pathology, 2009
- The Global Histone Modification Pattern Correlates with Cancer Recurrence and Overall Survival in Gastric AdenocarcinomaAnnals of Surgical Oncology, 2008
- Epigenetics in CancerNew England Journal of Medicine, 2008
- Polycomb silencers control cell fate, development and cancerNature Reviews Cancer, 2006
- Stem Cells and CancerCell, 2004
- Role of Histone H3 Lysine 9 Methylation in Epigenetic Control of Heterochromatin AssemblyScience, 2001